✦ LIBER ✦

Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: An Analysis From the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial

✍ Scribed by Hitinder S. Gurm; Ian J. Sarembock; Dean J. Kereiakes; John J. Young; Robert A. Harrington; Neal Kleiman; Frederick Feit; Kathy Wolski; John A. Bittl; Robert Wilcox; Eric J. Topol; A. Michael Lincoff

Book ID: 119265004
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 129 KB
Volume: 45
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2005.02.074

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of bivalirudin versus heparin

Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial)

✍ A.Michael Lincoff; John A Bittl; Neal S Kleiman; Ian J Sarembock; J.Daniel Jackm 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 107 KB

Outcomes of patients with acute coronary

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial

✍ Vivek Rajagopal; A. Michael Lincoff; David J. Cohen; Hitinder S. Gurm; Tingfei H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 113 KB

Ischemic and bleeding outcomes in women

Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: A subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial

✍ Matthews Chacko; A. Michael Lincoff; Katherine E. Wolski; David J. Cohen; John A 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Provisional glycoprotein IIb/IIIa blocka

Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial

✍ J. Emilio Exaire; Samuel M. Butman; Ramin Ebrahimi; Neal S. Kleiman; Robert A. H 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 179 KB

DOES TRIPLE THERAPY WITH CILOSTAZOL REDU

DOES TRIPLE THERAPY WITH CILOSTAZOL REDUCE THE RISK OF RESTENOSIS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION? INSIGHTS FROM A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

✍ Amita Singh; Michael Fingerhood; Frederick Feit; Sripal Bangalore 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 255 KB

The use of intravenous enoxaparin in ele

The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: Results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial

✍ Harvey D. White; Richard Gallo; Marc Cohen; Ph. Gabriel Steg; Philip E. Aylward; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 357 KB